Group 1 - China Pacific Insurance's subsidiary, China Pacific Life, reported a cumulative premium income of 241.32 billion yuan for the first ten months, a year-on-year increase of 9.9% [1] - China Pacific Property Insurance, another subsidiary, achieved a cumulative premium income of 173.57 billion yuan, with a year-on-year growth of 0.4% [1] - Nocera Biopharma reported a net loss of 64.41 million yuan for the first three quarters, despite a revenue increase of 59.85% to 1.115 billion yuan [1] Group 2 - Founder Securities received approval from the China Securities Regulatory Commission to issue short-term corporate bonds not exceeding 5 billion yuan [1] - Haicheng Bonda's director plans to reduce his stake by up to 0.97%, equating to 198,400 shares [1] - Yuyuan Group intends to repurchase shares worth between 200 million and 300 million yuan, with a maximum price of 8.60 yuan per share [1] Group 3 - Huaren Shuanghe's subsidiary passed the GMP compliance inspection for a specific diabetes medication [4] - Lichong Group received project notifications from three international automotive manufacturers, with expected sales amounting to approximately 1.135 billion yuan [6] - Deyang Co. is planning to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy [7] Group 4 - Longxin General announced the transfer of its entire stake in a subsidiary for 105.6 million yuan, and also plans to divest another stake for 1 yuan due to poor performance [16] - Kangda New Materials decided to terminate the acquisition of a semiconductor company due to unsatisfactory due diligence progress [17] - Lu'an Environmental reported a 3.28% year-on-year increase in coal sales for October, totaling 3.78 million tons [18] Group 5 - Shanghai Port Group plans to invest 2 billion yuan to establish a new holding company with several state-owned enterprises [20] - Borui Pharmaceutical's new drug for obesity treatment has received clinical trial approval [23] - Silver Dragon Co. has completed the registration of a new energy industry fund focusing on high-growth potential projects [24] Group 6 - Hengrui Medicine received approval for a clinical trial of a prostate cancer drug [11] - Baiji Shenzhou reported a net profit of 1.139 billion yuan for the first three quarters, marking a turnaround from losses [36] - Huasheng Pharmaceutical's special medical food product has received registration certification [60]

Group 1 - The company Infit (300582.SZ) announced that its wholly-owned subsidiary, Hangzhou Infit Equity Investment Co., Ltd., will invest in Qinghai Spring Warm Flower Biotechnology Co., Ltd. and its existing shareholders through a capital increase and share transfer agreement [1] - The investment includes a cash contribution of 13.44 million yuan to increase the registered capital of Spring Warm Flower by 1.344 million yuan, with the remaining amount recorded as capital surplus [1] - After the transaction, the company will directly hold 2.62% of the equity in the target company and indirectly hold 3.04% through Blincao Biotechnology [1] Group 2 - This transaction allows the company to deepen its application scenarios in plant/biological lighting, accurately understand customer needs, and iteratively improve LED driver power supplies, sensors, and control systems [2] - The strategic shift from a "single hardware supplier" to a "system solution provider" will enhance customer loyalty and technical barriers, maintaining the company's competitive advantage in the plant (biological) lighting segment [2]

Group 1 - The company announced that its wholly-owned subsidiary, Hangzhou Infit Investment Co., Ltd., will invest 13.44 million yuan in Qinghai Spring Warm Flower Biotechnology Co., Ltd. and acquire shares from existing shareholders [1] - After the transaction, the company will directly hold 2.62% of the target company's equity and indirectly hold 3.04% through Blincao Biotechnology [2] - This transaction aims to enhance the application scenarios of plant/biological lighting, allowing the company to better understand customer needs and transition from a "single hardware supplier" to a "system solution provider" [2]

Core Viewpoint - The company Infinitus (300582.SZ) has approved a capital increase and equity transfer agreement involving its wholly-owned subsidiary, aiming to invest in Qinghai Chunwarm Biotechnology Co., Ltd. and its existing shareholders [1][2] Group 1: Investment Details - Infinitus plans to invest a total of 13.44 million yuan in cash, which includes a capital increase of 1.344 million yuan and the remainder as capital premium [1] - The company will acquire all registered capital of 1.56 million yuan from Blincao Biotechnology Co., Ltd. for 1.56 million yuan [1] - After the transaction, Infinitus will hold 2.62% direct equity in the target company and an additional 3.04% indirectly through Blincao Biotechnology [1] Group 2: Profit Guarantees - The controlling shareholder and chairman, Guichaohua, has committed to a buyback agreement if the target company's net profit is negative for the years 2026 and 2027, or if the cumulative net profit for 2026, 2027, and 2028 does not reach 60 million yuan [2] - This transaction is classified as a related party transaction due to the buyback commitment [2]

Core Viewpoint - Infinitus (300582) announced an investment through its wholly-owned subsidiary, Hangzhou Infinitus Equity Investment Co., Ltd., to acquire stakes in Qinghai Spring Blossoms Biotechnology Co., Ltd. and Hangzhou Bincao Biotechnology Co., Ltd. [1] Group 1: Investment Details - The company plans to invest 13.44 million yuan in cash to subscribe for an additional registered capital of 1.344 million yuan in Qinghai Spring Blossoms, with the remaining amount recorded as capital surplus [1] - The company will also acquire all registered capital of 1.56 million yuan from Xu Danhong and Gao Minjian in Hangzhou Bincao Biotechnology Co., Ltd. [1] - After the transactions, the company will directly hold 2.62% of Qinghai Spring Blossoms and indirectly hold 3.04% through Bincao Biotechnology [1] Group 2: Technology and Business Focus - Qinghai Spring Blossoms utilizes biotechnology, plant growth lighting, and environmental control technology to standardize the supply of high-value-added raw materials [1] Group 3: Management Commitment - The company's actual controller and chairman, Guichao Hua, will assume a potential buyback obligation for this investment [1]

Core Viewpoint - Infinet (300582.SZ) has approved a capital increase and equity transfer agreement involving its wholly-owned subsidiary, Hangzhou Infinet Equity Investment Co., Ltd., and Qinghai Chunwarm Biotechnology Co., Ltd., indicating a strategic investment move in the biotechnology sector [1] Group 1: Investment Details - Infinet Equity Investment plans to invest CNY 13.44 million in Chunwarm Biotechnology, with CNY 1.344 million allocated to the new registered capital and the remainder as capital premium [1] - The company will also acquire all registered capital of Blincao Biotechnology for CNY 1.56 million, which is part of the overall transaction [1] - Upon completion of the transaction, Infinet Equity Investment will hold 2.62% direct equity in Chunwarm Biotechnology and an indirect 3.04% through Blincao Biotechnology [1] Group 2: Profit Guarantees - The controlling shareholder, GUICHAOHUA, has committed to a profit guarantee, allowing Infinet Equity Investment to demand a buyback of its shares if Chunwarm Biotechnology's net profit is negative over 2026 and 2027, or if the combined net profit for 2026, 2027, and 2028 does not reach CNY 60 million [2] - This transaction is classified as a related party transaction due to the involvement of the controlling shareholder [2]

证券代码：300582 证券简称：英飞特 公告编号：2025-067 英飞特电子（杭州）股份有限公司 关于对外投资及上市公司实控人对本次投资承担或有回购义务 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、交易概述 （一）对外投资基本情况 英飞特电子（杭州）股份有限公司（以下简称"英飞特"、"公司"、"上市公 司"）于2025年11月12日召开第四届董事会第十八次会议审议通过了《关于对外 投资及上市公司实控人对本次投资承担或有回购义务的议案》。 公司董事会同意公司全资子公司杭州英飞特股权投资有限公司（以下简称 "英飞特股权投资"、"杭州英飞特"或"投资人"）与青海春暖花开生物技术有限 公司（以下简称"春暖花开"或"标的公司"）及其现有股东浙江塞鼎新能源科技 有限公司（以下简称"塞鼎新能源"）、杭州博瑞昊华能源管理合伙企业（有限 合伙）（以下简称"博瑞昊华"）、杭州炎虫生物技术有限公司、杭州彬草生物 技术有限公司（以下简称"彬草生物"）、海东河湟实业（集团）有限公司（以 下简称"河湟实业"）和春暖花开的控股股东许丹红签署《增资认购协议》，并 与彬草生物及彬草 ...

证券代码：300582 证券简称：英飞特 公告编号：2025-068 英飞特电子（杭州）股份有限公司 关于召开 2025 年第二次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东会届次：2025 年第二次临时股东会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交 易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号— 创业板上市公司规范运作》等法律、行政法规、部门规章、规范性文件及 《公司章程》的有关规定。 4、会议时间： （1）现场会议时间：2025 年 11 月 28 日 14:40 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间 为 2025 年 11 月 28 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易 所互联网投票系统投票的具体时间为 2025 年 11 月 28 日 9:15 至 15:00 的任意 时间。 5、会议的召开方式：现场表决与网络投票相结合。 6、会议的股权登记日 ...

英飞特电子（杭州）股份有限公司 第四届董事会第十八次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：300582 证券简称：英飞特 公告编号：2025-066 一、董事会会议召开情况 1、英飞特电子（杭州）股份有限公司（以下称"公司"或"上市公司"）第四 届董事会第十八次会议的会议通知于 2025 年 11 月 10 日通过邮件等方式送达至 各位董事，通知中包括会议的相关材料，同时列明了会议的召开时间、地点、 内容和方式。 2、本次董事会于 2025 年 11 月 12 日在公司会议室，以现场及通讯相结合 的方式召开。 3、本次董事会应出席董事 9 名，实际出席董事 9 名，其中现场出席会议的 董事 3 人，董事黄美兰、F MARSHALL MILES、应林光、竺素娥、孙笑侠、张 军明以通讯方式参加会议。 4、本次董事会由董事长 GUICHAO HUA 先生主持，公司高级管理人员列 席了本次董事会。 5、本次会议的召集、召开和表决程序符合《中华人民共和国公司法》等法 律法规和《公司章程》的有关规定。 二、董事会会议审议情况 会议审议并通 ...

Core Viewpoint - The company has approved several resolutions during its board meeting, including capital investments and acquisitions in the biotechnology sector [1] Group 1: Investment Activities - The company’s wholly-owned subsidiary, Yingfei Investment, will invest 13.44 million yuan to subscribe for an additional registered capital of 1.344 million yuan in Qinghai Chunwan Huakai Biotechnology Co., Ltd [1] - Yingfei Investment will acquire 100% of the registered capital of Bincao Biotechnology for 15.6 million yuan, resulting in a direct and indirect ownership of 5.66% in the target company [1] - The controlling shareholder and chairman, Guichaohua, will assume a contingent repurchase obligation for the investment [1] Group 2: Capital Increase - The company has agreed to increase the capital of Yingfei Investment by 25 million yuan, raising its registered capital to 52 million yuan [1] Group 3: Future Meetings - The company plans to hold its second extraordinary general meeting of shareholders on November 28, 2025 [1]